Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Court Denies Pfizer Request To Halt Sales Of Ivax’ Neurontin Generic

This article was originally published in The Pink Sheet Daily

Executive Summary

A federal judge rejects Pfizer’s motion for a temporary restraining order and preliminary injunction to halt Ivax’ marketing of gabapentin tablets. Court rules that because Ivax’ generic is not AB-rated to Neurontin, Pfizer failed to establish irreparable harm.
Advertisement

Related Content

Purepac, Teva Launch Neurontin Generics; Pfizer's Greenstone Unit Follows
Purepac, Teva Launch Neurontin Generics; Pfizer's Greenstone Unit Follows
Pfizer Asks Court To Keep Purepac’s Neurontin Generic Off The Market
Pfizer Asks Court To Keep Purepac’s Neurontin Generic Off The Market
Ivax Launches Neurontin Generic As User Fee Date For Pfizer's Pregabalin Nears
Ivax Launches Neurontin Generic As User Fee Date For Pfizer's Pregabalin Nears

Topics

Advertisement
UsernamePublicRestriction

Register

PS060354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel